© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, iTeos Therapeutics, Inc. (ITOS) shows an Average True Range (ATR) of 0.07 and an Enterprise Value of 133.74M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into ITOS's underlying financial health and market activity.
iTeos Therapeutics, Inc. (ITOS) technical indicators as of January 1, 2026: the SMA 20 is 0.21%, SMA 50 at 0.17%, and SMA 200 at 22.49%. The RSI 14 value is 54.76, suggesting its current momentum. These technical analysis signals help assess ITOS's price trends and potential future movements.
iTeos Therapeutics, Inc. (ITOS) stock performance overview as of January 1, 2026: The 52-week high is $11.35 (currently -42.43% below), and the 52-week low is $4.8 (currently 111.46% above). Over the past year, ITOS's performance is N/A, compared to the S&P 500's 12.29% change.
According to market data, iTeos Therapeutics, Inc. (ITOS) stock's recent performance metrics show that over the last month, ITOS is 0.3%, with a Year-to-Date (YTD) performance of 32.16%. Over the past year, the stock has seen a N/A change. These figures summarize ITOS's price movements across various periods, reflecting its historical returns.
According to current financial data, ITOS stock's P/E (TTM) ratio is -2.18, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for ITOS, including P/S (N/A), P/B (0.90), and P/FCF (-4.13), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.